Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs The Coca-Cola Co K (KO) Price & Performance

Inovio Pharmaceuticals IncTrade
The Coca-Cola Co KTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs The Coca-Cola Co K — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $76.09M), while The Coca-Cola Co K trades at $86.36 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 4912.1× Inovio Pharmaceuticals Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOKO
Market Cap
$76.09M$373.76B
Sector
HealthConsumer Staples
52-Week High
$2.87$89.08
52-Week Low
$0.66$65.67
Enterprise Value
$47.10M$400.93B
Volume
14,630,257
Dividend Yield
2.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

The Coca-Cola Co K

Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 forecast. Key valuation ratios include a P/E of 26.09 and ROE of 44.23%, while cash flow trends show robust operational performance. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.

The outlook remains positive with a consensus price target of $95.83, implying 10.3% upside. Strengths include a 64-year dividend growth streak and high profitability, but risks involve regional demand divergence and elevated debt levels. Analyst sentiment is bullish with 60% buy ratings, supporting a favorable investment case for long-term holders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO